Feeling the effects of the coronavirus pandemic, Californian biotech Amgen (Nasdaq: AMGN) reported mixed results for the final quarter of 2020, with rising revenues but declining profits.
Matching analysts’ expectations, revenues were up 7% at $6.6 billion, with earnings increasing 3% to $2.2 billion, which equates to $3.81 a share.
While revenues were driven by higher volume growth, this effect was partially offset by lower net selling prices and the effects of the COVID-19 pandemic.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze